
Sign up to save your podcasts
Or
In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.
Subscribe to Eagle’s Eye View
4.7
128128 ratings
In this week’s View, Dr. Eagle looks at the CATHEDRAL-HF Trial and its study of carvedilol’s effectiveness as a monotherapy in heart failure with improved ejection fraction (HFimpEF). He then discusses the use of modifiable lifestyle factors to lower the risk of cardiac conduction disease. Finally, Dr. Eagle explores the use of amiloride versus spironolactone for the treatment of resistant hypertension.
Subscribe to Eagle’s Eye View
131 Listeners
325 Listeners
161 Listeners
865 Listeners
496 Listeners
31 Listeners
3,336 Listeners
1,095 Listeners
61 Listeners
39 Listeners
194 Listeners
519 Listeners
349 Listeners
427 Listeners
37 Listeners